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Receptor-mediated uptake of IDL and LDL from nephrotic patients by
glomerular epithelial cells. Although hyperlipidemia is a well-recognized
complication of the nephrotic syndrome, the precise interaction of
human glomerular cells and human lipoproteins, abnormal in lipid and
protein composition, has not been clearly defined. This study examines
receptor mediated binding, internalization and degradation as well as
intracellular cholesterol metabolism of apoB-lO0 containing LDL and
apoB,E containing IDL, isolated from patients with the nephrotic
syndrome (N = 6), in human glomerular epithelial cells and skin
fibroblasts. In the patients, serum LDL cholesterol level was increased
threefold and IDL elevenfold as compared to healthy subjects. IDL of
nephrotic patients contained 72% morecholesterol than IDL of healthy
controls. No difference in lipid/protein composition was found in the
LDL density range. Therefore, nephrotic and control LDL showed
identical afilnities for receptor mediated binding, internalization and
degradation. Furthermore, inhibition of intracellular sterol synthesis
and cholesteryl ester formation after incubation with LDL was compa-
rable. In contrast, cholesterol-rich IDL of nephrotic patients was taken
up by glomerular epithelial cells with higher affinity than LDL and
control IDL, as well as intracellular sterol synthesis was suppressed
more effectively than by control IDL. The cholesterol esterification rate
of IDL from patients was enhanced 3.5-fold as compared to control
IDL. In comparison to fibroblasts, glomerular epithelial cells showed
about 15% of the maximal capacity for LDL uptake, but 31% for IDL
from nephrotic patients. The data indicate that hypercholesterolemia of
nephrotic origin cannot be explained by reduced ligand binding for
LDL. ApoE containing IDL, which accumulate in nephrotic patients,
were avidly taken up by glomerular epithelial cells via receptor depen-
dent pathway. These lipoproteins could therefore play the predominant
role in glomerular lipid accumulation and development of glomerulo-
sclerosis.
Quantitative abnormalities in lipoprotein metabolism are the
most striking features of the nephrotic syndrome. Total serum
cholesterol, triglycerides and phospholipids as well as apoli-
poprotein B, C and E are increased [1]. Qualitative alterations
are characterized by cholesterol enrichment in the very-low
density lipoprotein (VLDL) fraction as also demonstrated by an
increased cholesterol/triglyceride ratio [2, 3]. A similar abnor-
mality has been found in the LDL density range with an
enrichment of both, triglyceride and cholesterol [4], but this has
not been confirmed by others [1]. Furthermore, in patients with
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the nephrotic syndrome the IDL fraction is quantitatively
increased and characterized by a significant increase of choles-
terol at the expense of triglyceride [2]. Increases in serum
lipoprotein concentration could be due to increased synthesis
[5], impaired catabolism [6], or both [7]. Whether delayed
catabolism could also be due to an abnormal composition of
lipoproteins or an altered receptor uptake has not yet been
studied.
The presence of lipid in the kidney has been described in a
wide range of renal disease. In focal and segmental glomerulo-
sclerosis lipid deposition and foam cell formation are almost
always present [8]. Moorhead et al [9] hypothesized that
accumulation of lipids may injure glomerular cells and predis-
pose to glomeruloscierosis. Further investigations have postu-
lated that glomerulosclerosis and atherosclerosis share common
pathogenic mechanisms [10, 11]. Animal experiments have
demonstrated that lipid-lowering therapy ameliorates the pro-
gression or even suppresses the development of focal and
segmental glomeruloscierosis in chronic aminonucleoside ne-
phrosis [12]. Glomerular epithelial cells (GEC) represent the
major cell type of the glomerulus in terms of volume [13]. They
are directly exposed to high concentrations of lipoproteins in
various renal diseases which are accompanied by the nephrotic
syndrome. Although characterized by relatively low LDL-
receptor activity, GEC clearly exhibit receptor-mediated li-
poprotein uptake and high affinities for j3-VLDL from choles-
terol fed rabbits [14]. Based on these data, we hypothesized that
human glomerular cells and skin fibroblasts could exhibit al-
tered receptor mediated uptake and intracellular cholesterol
metabolism when exposed to lipoproteins isolated from patients
with the nephrotic syndrome. These experiments could further
characterize some of the mechanisms by which cellular accu-
mulation of lipids occurs in renal disease.
Methods
Patients
Blood was drawn from six patients (3 female, 3 male, mean
age 42 8 years; range 26 to 76 years) with the nephrotic
syndrome and serum was isolated for the studies performed in
vitro. The histologic findings of the patients, as determined by
renal biopsy, as well as clinical and laboratory data are shown
in Tables 1 and 2. At the time of sampling all patients were
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Table 1. Clinical details of nephrotic patients
Patient Sex
Age
years
Weight
kg
BMI
kg/rn2
Renal
histology Treatment
AE F 53 62 25.6 MON none
JE M 36 80 24.2 FSGS frusemide
HC F 26 46 18.0 MCGN piretanid, enalapril
ML F 76 55 22.0 MGN triamterene, hydrochlorothiazide
EH M 35 92 29.7 MON xipamide
WM M 26 86 27.8 MON frusemide
Mean 3F/3M 42 70 24.6
SEM 8 7.5 1.7
Abbreviations are: MON, membranous glomerulonephritis; FSGS, focal and segmental glomerulosclerosis; MCON, minimal change glomeru-
lonephritis.
Table 2. Laboratory characteristics of nephrotic patients
Patient
Serum
creatinine
rng/dl
Serum
albumin
glliter
Quantitative
proteinuria
g/24 hr
AE 0.9 23 8.3
JE 0.8 21 13.0
HC 0.8 19 15.6
ML 0.8 24 8.0
EH 0.9 21 12.3
WM 1.3 17 19.6
Mean 0.9 20.8 12.8
SEM 0.08 1.0 1.8
Table 3. Serum lipid concentrations in patients with the nephrotic
syndrome and healthy subjects (N = 6)
Cholesterol
Subject mg/dl Triglyceride VLDL-C LDL-C HDL-C
Nephrotic
AE 578 325 132 401 45
JE 685 620 223 424 38
HC 725 418 141 521 63
ML 574 159 26 429 119
EH 412 319 84 298 30
WM 311 180 46 233 32
Mean 548 337 109 384 55
SEM 65 69 29 42 14
Controls
Mean 190 81 17 128 45
SEM 10 10 2 7 4
classically nephrotic exhibiting marked edema, severe hy-
poalbuminemia and hyperlipidemia. No patient was on immu-
nosuppressive or lipid lowering drugs. Informed consent was
obtained from all patients. Six normolipidemic healthy subjects,
matched for apolipoprotein E phenotype, acted as controls.
Materials
'251-sodium iodide and 2-['4C] sodium acetate were obtained
from Amersham-Buchier (Braunschweig, Germany) as well as
9, 10 (n)-[3HJ oleic acid from Du Pont (Dreieich, Germany).
Collagenase I was purchased from Sigma (Deisenhofen, Ger-
many), and DMEM/F12 medium, fetal calf serum (FCS), glu-
tamine, sodium pyruvate, HEPES buffer, penicillin-streptomy-
cm, and non-essential amino acids were all purchased from
Seromed (Berlin, Germany). Insulin-transferrin-sodium selenite
was obtained from Boehringer-Mannheim (Mannheim, Germa-
Table 4. Lipid/protein composition of low density lipoprotein in
patients with the nephrotic syndrome and healthy subjects (N = 6)
Subject Chol TO PL Protein FC CE
Nephrotic
AE 40.4 5.6 25.2 28.7 9.2 31.2
JE 57.0 7.6 16.8 18.0 6.8 50.2
HC 39.5 9.8 25.0 25.6 11.4 28.1
ML 49.0 5.5 22.4 22.9 10.6 38.5
EH 42.0 5.1 24.7 29.3 10.0 31.9
WM 35.3 9.0 26.3 28.7 11.1 24.3
Mean 43.8 7.1 23.4 25.4 9.9 34.0
SEM 3.2 0.8 1.4 1.8 0.7 3.7
Controls
Mean 40.6 5.5 26.8 26.9 11.5 29.2
SEM 0.9 0.7 0.7 1.2 0.9 1.3
Data are given in %. Triglyceride (TG), phospholipid (PL), choles-
terol (chol), and protein represent all components of the total lipopro-
tein. Abbreviations are: FC, free cholesterol; CE, cholesterol ester.
Table 5. Lipid/protein composition of intermediate density lipoprotein
in patients with the nephrotic syndrome and healthy subjects (N = 6)
Subject Chol TO PL Protein FC CE
NephroticAE 30.0 19.2 22.0 28.7 8.2 21.7
JE 37.6 21.6 25.0 15.6 9.5 28.0
HC 30.5 29.4 22.0 18.0 9.1 21.4
ML 32.0 28.0 20.0 20.0 8.2 23.8
EH 37.8 21.3 24.5 16.6 10.9 27.0
WM 33.0 24.0 22.7 21.0 8.2 24.8
Mean 335b 239b 22.7 200b 9.0 245b
SEM 1.4 1.6 0.7 1.9 0.4 1.1
Controls
Mean 19.2 33.8 19.8 27.6 8,2 12.2
SEM 2.4 1.1 2.1 2,9 0.9 1.6
Data are given in %. Triglyceride (TG), phospholipid (PL), choles-
terol (chol), and protein represent all components of the total lipopro-
tein. Abbreviations are: FC, free cholesterol; CE, cholesterol ester.
Patients studied for IDL uptake
b p < 0.01 vs. controls
ny). Rabbit anti-mouse IgG, pig anti-rabbit IgG, peroxidase
anti-peroxidase IgG produced in rabbit, antibodies for factor
VIII, vimentin and cytokeratin were all from Dakopatts (Ham-
burg, Germany). Cholesterol, triglycerides and phospholipids
were determined enzymatically using Wako reagents (Wako,
Neuss, Germany). Antibody to apolipoprotein B was purchased
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Fig. 1. Characteristic pattern of apolipoprotein
distribution in the various lipoprotein density
classes, isolated by ultracentr jfugation from aE patient with the nephrotic syndrome (3%
A polyacrylamide gelelectrophoresis in the
presence of sodium dodecyl sulfate).
Abbreviations are: LS, low molecular weight
standard; 1, HDL nephrotic syndrome; 2, HDL
control; 3, LDL nephrotic syndrome; 4, LDL
control; 5, IDL nephrotic syndrome; 6, IDL
control; 7, VLDL nephrotic syndrome; 8,
VLDL control; B, apolipoprotein B-100; E,
apolipoprotem E, Al, apolipoprotem Al; HS,
high molecular weight standard.
from Beckman (Palo Alto, California, USA) and apolipoprotein
E from International Immunology Corporation (Murrista, Cal-
ifornia, USA).
Cell cultures
Fibroblasts derived from skin biopsies of healthy subjects
were maintained in Dulbecco's minimal essential medium,
which contained 25 mrt NaHCO3, 20 mM HEPES buffer, pH 7.4
and 10% FCS. Kidney tissue was obtained from patients
undergoing tumor nephrectomy and glomeruli were isolated by
sieving technique as previously described [15]. In brief, isolated
glomeruli were incubated with collagenase I for 30 minutes at
37°C. After washing twice in the DMEM/F12 medium and
following sedimentation cycles, aside from glomeruli almost no
other particles could be detected. Encapsulated glomeruli were
not observed visually. They were suspended in DMEM/F12
culture medium, supplemented with 10% heat-inactivated FCS,
glutamine 2.5 mmollliter, sodium pyruvate 0.1 mmol/liter,
HEPES buffer 5 mmollliter, penicillin IO U/liter, streptomycin
100 mg/liter, non-essential amino acids (bOx) 0.1 X and
insulin-transferrin-sodium selenite supplement 5 mg/liter. Gb-
meruli were plated onto Petri dishes coated with collagen
(Vitrogen 100R, Celtrix, Palo Alto, California, USA). Collagen
coated plastic material was recently shown to facilitate the
outgrowth of glomerular epithelial cells [16]. After one week in
primary culture GEC began to sprout around the glomeruli.
After destruction of residual mesangial cells with a scalpel blade
GEC were subcultured. Fibroblast contamination was excluded
by growing the cells for two weeks in a L-valine free medium
according to Gilbert and Migeon [17]. Cells from the fifth to the
tenth subculture were used for all experiments.
Morphologic and immunochemical studies
Glomerular epithelial cells in culture could be identified with
phase-contrast microscopy. They showed an epithelial mor-
phology, a polyhedral shape and a cobblestone-like appearance
when confluency was reached. All cell lines showed the same
immunological characteristics as described by Kreisberg and
Karnowski [18]. Immunochemical characterization was per-
formed using the peroxidase-antiperoxidase (PAP) method ac-
cording to Bross et al [19]. Confluent cell layers were fixed with
methanol at —20°C. Cells were preincubated for 30 minutes
with Dulbeccos's phosphate saline buffer (PBS-buffer) contain-
ing gelatin 5% and serum albumin 22% to block nonspecific
protein binding. The cells were then incubated with a mouse
anti-human IgG antibody for 30 minutes. The following "sand-
wich" antibodies were each incubated for 15 minutes: rabbit
anti-mouse IgG, pig anti-rabbit IgG, peroxidase anti-peroxidase
IgG produced in rabbit. After staining the immuncomplex with
diaminobenzidine, brown granules in PAP-positive cells could
be observed by light microscopy. Cells not incubated with the
primary antibody failed to show any staining excluding nonspe-
cific reactions. Antibodies for factor VIII did not stain, thus
excluding endothelial cells. Cells were homogenously positive
for vimentin and cytokeratin, thus excluding mesangial cells.
Therefore, the cells studied showed the morphological and
immunological characteristics described by others for GEC [20,
21]. At present, it is not possible to determine specifically
whether GEC in culture originate from visceral or parietal
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epithelium. Cytokeratin negativity and vimentin positivity has
been suggested as a criterion for visceral origin [22], but this is
not generally accepted [23].
Lipid and apolipoprotein analysis
Very-low density lipoprotein (VLDL) was isolated by analyt-
ical ultracentrifugation [24] with modifications previously de-
scribed [25]. The concentration of LDL-lipids was determined
by the difference between VLDL-free serum and the supranate
of this fraction after precipitation of LDL by phosphotuncstic
acid/MgCI2. Cholesterol, triglycerides and phospholipids were
determined enzymatically on a Wako R-30 analyzer. The coef-
ficient of variation for cholesterol and triglyceride as well as the
determination of LDL varied between I and 3%. Apolipopro-
tein B was determined by kinetic nephelometry using a com-
mercial kit and the "Array" nephelometer (Beckman). Apoli-
0 20 40 60 80 100
FIg. 2. Concentration dependent uptake of '231-LDL of healthy
control subjects (A) and patients with the nephrotic syndrome () by
cultures of human skin fibroblasts. Data are given as mean SEM of
6 patients and 6 healthy controls. All measurements were carried out
in triplicate. (A) Receptor-specific heparin releasable binding at 37°C.
(B) Receptor-specific internalization at 37°C. (C) Receptor-specific
degradation at 37°C. Insets: Scatchard analyses are generated from
saturation curves.
poprotein E was measured by endpoint nephelometry using a
"BNA" nephelometer from Behring (Marburg, Germany). The
specificity of antiserum was evaluated by immunoelectrophore-
sis for apoB and immunoflxation in agarose for apoE. Apoli-
poprotein E phenotyping was performed by immunofixation in
agarose as described previously [26]. The apolipoprotein com-
position of the VLDL, IDL and LDL fraction was further
characterized by SDS-PAGE on 3% polyacrylamide slab gels
[27]. The protein content of cells and lipoproteins was deter-
mined by the Lowry method.
Lipoprotein isolation and separation
Blood from the nephrotic patients as well as the six healthy
donors was drawn into tubes containing 10% sodium-citrate
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after a 12-hour overnight fast. Lipoproteins of patients were
isolated in parallel with the control subjects by sequential
ultracentrifugation [28]. After separation, VLDL, IDL and
LDL were dialyzed against 5 mrt Tris/HCI pH 7.4, 154 mM
NaCI, 250 mM EDTA, and sterilized by passage through a 0.45
Millipore filter.
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Fig. 3. Concentration dependent uptake of '251-LDL of healthy
control subjects (•) andpatients with nephrotic syndrome (0) by
cultures of human glomerular epithelial cells. Data are given as mean
SEM of6 patients and 6 healthy controls. All measurements were
,, carried out in triplicate. (A) Receptor-specific heparin releasableVU QU I VU binding at 37°C. (B) Receptor-specific internalization at 37°C. (C)
Receptor-specific degradation at 37°C. Insets: Scatchard analyses are
'251-LDL, pgprotein/mImedium generated from saturation curves.
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Table 6. Concentration dependent uptake of 1251-IDL and '251-LDL
from patients with the nephrotic syndrome by monolayer cultures of
human glomerular epithelial cells (GEC) and skin fibroblasts (FIB)
GEC FiB
'Vn,ax Kd Vmx Kd
Control LDL
Specific binding 66 23.4 644 16,4
Specific internalization 135 23.8 2,476 13.6
Specific degradation 1,024 21.4 6,181 9.5
Nephrotic LDL
Specific binding 52 17.6 646 18.2
Specific internalization 118 16.5 2,551 13.5
Specific degradation 916 12.4 6,098 8.0
Control IDL
Specific binding 38 16.5 191 26.9
Specific internalization 158 18.1 1,248 28.3
Specific degradation 295 7.3 2,229 11.4
Nephrotic IDL
Specific binding 62 7.4 180 3.4
Specific internalization 194 8.3 1,744 6.1
Specific degradation 1,073 5.1 2,240 2.4
Mean SEM from 6 LDL experiments and 3 IDL experiments. All
measurements were done in triplicate. Data are obtained by scatchard
plot analysis. Vmax is given in nglmg cell protein and Kd in pg/mI
medium.
Preparation of lipoprotein deficient serum (LDS)
Human plasma was rendered lipoprotein deficient by a two
step ultracentrifugation procedure (150,000 x g for 48 hr at
10°C), adjusting the plasma to d = 1.250 g/mi by addition of
solid KBr. After removal of all lipoprotein fractions LDS was
dialyzed against 154 mrt NaCl, 250 msi EDTA, 5 mr'i HEPES,
pH 7.4. Thereafter, LDS was heat-inactivated at 54° for one
hour and sterilized by passage through a 0.45 pm Milhipore
filter. Finally the protein content was adjusted to 40 mg/mI.
Radioiodination of IDL and LDL
Radioiodination of IDL and LDL was performed by the
method of McFarlane [29] modified for lipoproteins by Bilhei-
mer, Eisenberg and Levy [30]. Per mg lipoprotein-protein 100 d
glycine buffer (1 M, pH 10), 25 mCi '251-sodium iodide and 30 p1
iodine-monochloride (10 mM) were added. Most unbound io-
dine was removed by passage through a Sephadex G-25 column
and by dialyzing against buffer containing 154 m NaCI, 250
mM EDTA pH 7.4. The final preparations of 1251-IDL and
'251LDL were sterilized by passage through a 0.45 pm Milli-
pore filter and protein content was estimated by using Lowry
method.
Assay for binding, internalization and degradation of
lipoproteins
To induce maximal apo B,E receptor activity, GEC were
incubated in medium that contained 10% LDS instead of FCS.
After 48 hours, monolayers were washed with PBS, and fresh
LDS containing medium was added together with '251-labeled
lipoproteins with or without a 25-fold excess of unlabeled
lipoproteins. The cultures were incubated for five hours at 37°C
[31]. The medium was removed and the cells were placed on
ice. The culture dishes were then washed five times with a cold
buffer containing 154 ifiM NaCI, 50 mtvi Tris (pH 7.4) and 2
mg/mi bovine fatty acid-free serum albumin as described by
Goldstein, Kita and Brown [31]. Assays for binding, internal-
ization and degradation were performed by standard methods
[32]. The heparin releasable activity represents binding at 37°C.
After the release of cell surface bound activity by heparin,
monolayers were dissolved in I ml of 0.1 N NaOH and radio-
activity and protein were measured. The radioactivity in the
pellet was taken as a measure for internalization. Non-iodide
trichioroacetic acid (TCA)-soiuble radioactivity served as a
measure for lipoprotein degradation. Non-specific binding, in-
ternalization and degradation was defined as amount of the
lipoprotein taken up in the presence of 25-fold excess of
unlabeled ligand. All experiments were performed in triplicate.
Cellular sterol synthesis and cholesterol esterification
Cell cultures were incubated in 10% LDS containing DMEM
medium for 48 hours and thereafter with varying concentrations
of lipoproteins for 12 hours.
Cellular sterol synthesis. Incorporation of ['4C] acetate into
sterols was used to determine cellular sterol synthesis. After
preincubation one ml of medium containing 0.8 pCi of ['4C]
acetate and unlabeled carrier acetate (0.2 pmol/ml, specific
acitivity 4 pCiIpmol) was added to each dish and the incuba-
tions were continued for two hours at 37°C. After washing twice
with PBS/BSA medium and three times with PBS-buffer, cells
were dissolved in 2 ml of 0.1 N NaOH. Cell suspension was
ultrasonified and a portion was taken for determination of ['4C]
activity and protein content [30, 31]. One ml of 100% ethanol
and 0.2 ml of 90% KOH were added in order to saponify cell
lysate during three hours at 80°C. Non-saponifiable lipids were
extracted into 2.5 ml of hexane. The hexane layer was washed
once by the addition of 0.1 ifiM sodium acetate (2.5 ml). The
hexane phase was evaporated and ['4C] activity was measured.
All experiments were performed in duplicate.
Cellular cholesterol ester(/ication. Cellular cholesterol ester-
ification was performed as described elsewhere [14]. Preincu-
bation was done as described above. LDS medium containing I
pCi of 9, 10 (n)-[3H] oheic acid bound to fatty acid-free albumin
in a molar ratio of 1:4 was added to monolayer cultures (specific
activity 20 pCi/pmol and final [3H] oleate concentration of 50
nmol/ml). After two hours of incubation at 37°C, cells were then
washed with PBS, scraped into plastic tubes and pelleted by
centrifugation. Water (0.4 ml) was added and pellets were
homogenized by ultrasonification. An aliquot (0.2 ml) of ho-
mogenate was extracted with 25 volumes of chloroform/meth-
anol (2:1), and the chloroform phase was washed with 0.034%
MgCI2 (0.2 mlJml of chloroform/methanol extract). After wash-
ing, the chloroform phase was dried, resuspended in chloro-
form/methanol and chromatographed on silica gel thin-layer
plates using a solvent system hexane:diethylether:acetic acid
(83:16:1, vol/vol/vol). Ester bands comigrating with cholesteryl
oleate standard were scraped and [3H] oleate incorporated in
cholesteryl ester quantitated. The water homogenate of cultures
was used for measurement of cellular protein as well as direct
measurement of [3H] activity. All experiments were performed
in duplicate.
Statistical evaluation
Results are given as means SEM. The means of the
duplicate and triplicate determinations from each experiment
served as a single experiment. Comparison was performed by
paired or unpaired Student's t-test, as appropriate.
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Fig. 4. Concentration dependent uptake of '251-IDL of healthy
control subjects (open symbols) and patients with nephrotic
syndrome (N = 3; closed symbols) by cultures of human skin
fibroblasts (triangles) and glomerular epithelial cells (circles). Data
are given as mean SEM. All measurements were. carried out in
triplicate. For symbols without error bars the s.e.mean was less than
symbol size. (A) Receptor-specific heparin releasable binding at 37°C.15 20 (B) Receptor-specific internalization at 37°C. (C) Receptor-specific
degradation at 37°C. Insets: Scatchard analyses are generated from
saturation curves.
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Fig. S. inhibition of cholesterol synthesis by IDL and LDL of healthy subjects (open symbols) and patients with the nephrotic syndrome (closed
symbols) in human skin fibroblasts (triangles) and human glomerular epithelial cells (circles). Incorporation of ['4C] acetate into sterols is
expressed in picomol of acetate found in non-saponifiable lipids. Data are given as mean of three independent determinations. All measurements
were carried out in duplicate.
Results
Serum lipid concentration in nephrotic patients
Absolute values for serum lipids of patients with the ne-
phrotic syndrome as well as healthy subjects are given in Table
3. The patients exhibited 2.9-fold higher concentrations of
serum cholesterol and markedly higher levels of serum triglyc-
erides. Levels of VLDL cholesterol and LDL cholesterol in
nephrotic patients were also higher than those in healthy
subjects, but HDL cholesterol was not different. Both, patients
and healthy subjects were matched for apoE3/E3 phenotype.
Lipid/protein composition of IDL and LDL from nephro:ic
patients
To investigate whether elevated serum lipids in nephrotic
patients were also accompanied by an abnormal lipoprotein
composition, the lipid/protein content of IDL and LDL was
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measured. In the LDL density class cholesterol, triglyceride,
phospholipid and protein content was not significantly different
in patients as compared to controls (Table 4). In contrast, IDL
particles of nephrotic patients exhibited higher concentrations
of cholesterol, whereas triglyceride content was reduced (Table
5). In particular, the elevation of cholesterol in IDL was entirely
due to an increase in esterified cholesterol. Furthermore, a
more pronounced apoE band could be identified by SDS-PAGE
in the IDL density range of nephrotic serum (Fig. 1). In
addition, determination of apoE by nephelometric methods
revealed a higher concentration in the nephrotic IDL as com-
pared to control IDL (1.5 0.5 vs. 0.8 0.1 mg/dl, respective-
ly).
Uptake of lipoproteins, isolated from nephrotic patients
To determine whether receptor-mediated cellular uptake of
lipoproteins from nephrotic patients was altered, various con-
centrations of 125! labeled IDL (1 to 20 g protein/mi) and LDL
(5 to 100 protein/mI) were incubated with both cell lines.
LDL-receptor activity was up-regulated by incubating in a
medium containing 10% LDS for 48 hours.
GEC as well as fibroblasts bound, internalized and degraded
normal and nephrotic LDL in a concentration and receptor
dependent manner, and the process was saturable. However,
GEC showed only 15% of the maximal uptake capacity as
compared to fibroblasts (Figs. 2 and 3). Scatchard plot analysis
revealed comparable Kd values and maximal capacities (Vmax)
for control and nephrotic LDL concerning binding, internaliza-
tion and degradation in both cell lines (Table 6). Due to the high
Fig. 6. Effects of IDL and LDL from healthy
subjects (open symbols) and patients with the
nephrotic syndrome (closed symbols) on
formation of cholesteryl esters in human skin
fibroblasts (triangles) and glomerular
___________ epithelial cells (circles). Cholesterol
esterification is given as picomol [3H]-oleate
formed/mg cell protein/2 hr. Data are given as
mean of three independent determinations. All
measurements were carried out in duplicate.
For symbols without error bars the SE mean
was less than symbol size.
turnover rate of IDL in serum of healthy subjects, normal iL
could not be isolated from one serum sample in qntities
allowing labeling of these lipoproteins with '25iodine. There.
fore, IDL from four apoE phenotype-matched healthy subjects
was pooled. In comparison to control IDL, cholesterol-rich
IDL of nephrotic patients was taken up by GEC and fibroblasts
with higher affinities in a concentration dependent and saturable
manner (Fig. 4). Maximal capacities for uptake of apoE-con-
taming IDL by GEC were higher as compared to LDL uptake.
The values for Kd in GEC were comparable to the values
obtained for binding, internalization and degradation in cultured
fibroblasts. However, the affinity of apoE-containing IDL was
considerably higher compared to LDL uptake (Fig. 4, Table 6).
Effect of JDL and LDL from nephrotic patients on cellular
sterol synthesis and cholesterol esteijfication
Incorporation of ['4C] acetate into sterols. To determine
whether nephrotic lipoproteins influence the regulation of intra-
cellular cholesterol metabolism, GEC and fibroblasts were
incubated with varying concentrations of IDL and LDL from
patients and healthy subjects. After 48 hours of incubation in
10% LDS-containing medium, cells were incubated for 16
hours with IDL or LDL. The presence of either nephrotic or
normal LDL at a lipoprotein concentration of 10 g protein/mi
medium inhibited sterol synthesis by 83.7 2.8 versus 81.7
3.1% in fibroblasts and 58.5 5.5 versus 55 6.2% in GEC,
respectively (Fig. 5). Sterol synthesis was more effectively
suppressed by addition of nephrotic IDL as compared to
control IDL. This was more effective in the low concentration
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range. At concentrations above 5 j.g protein/mi medium intra-
cellular enzymatic processes were probably already saturated.
Therefore, using higher lipoprotein concentrations, up to 10 g
protein/mi medium, the extent of inhibition was almost identical
(Fig. 5).
[3HJ-oleate incorporation into cholesteryl ester. Incorpora-
tion of oleate into cholesteryl ester was used as a measure of
effective cellular uptake of lipoproteins. In GEC and fibro-
blasts, no difference in the rate of cholesterol esterification
could be observed between control and nephrotic LDL (Fig. 6).
Fibroblasts showed an eightfold higher estenfication rate of
LDL cholesterol (at 50 g/ml medium) than GEC. In contrast,
both cell lines showed a higher cholesteryl ester formation rate
when incubated with cholesterol-rich nephrotic IDL compared
to control IDL (Fig, 6).
Discussion
Animal experiments have elucidated pathogenetic mecha-
nisms underlining a potential role of lipoproteins in glomerular
cell injury and progression of renal disease. Since lipoprotein
metabolism is different in rodents and humans, we utilized a
homologous system using human glomerular epithelial cells as
well as skin fibroblasts and human lipoproteins, isolated from
patients with the nephrotic syndrome, and studied receptor
dependent uptake and intracellular cholesterol metabolism. The
main findings were that glomerular epithelial cells in culture
expressed higher affinities towards apoB,E containing IDL than
apoB-100 containing LDL. The high affinity was accompanied
by a more enhanced rate of intracellular choiesteryl ester
formation, and suppressed sterol synthesis, after incubation
with IDL from nephrotic patients than with control IDL. In
contrast, nephrotic LDL showed no differences in uptake and
intracellular cholesterol metabolism as compared to control
LDL. These findings can be explained by the altered chemical
composition and apolipoprotein distribution of intermediate
density lipoproteins which accumulate in the serum of patients
with the nephrotic syndrome.
Hyperlipidemia of the nephrotic syndrome can result from
both increased synthesis [5] and reduced catabolism of lipopro-
teins [6, 7]. Reduced catabolism of triglyceride rich lipoproteins
in humans is proposed to be due to a decrease in lipoprotein
lipase activity, which can result in a delay in lipolysis and
accumulation of remnant particles. Cholesteryl ester transfer
protein (CETP) is responsible for distribution of cholesterol
esters among lipoproteins. Altered composition of IDL parti-
cles with an enrichment in cholesterol esters to the expense of
triglycerides, as found in the present study, could be consistent
with the assumption that lipoprotein particles of nephrotic
patients remain longer in the circulation than IDL of healthy
subjects or that CETP activity is enhanced [33]. The high
affinity to the receptor and the preferential uptake of IDL by
glomerular epithelial cells could result in a down-regulation of
the LDL-receptor (in vitro data not shown) and could therefore
be one cause for accumulation of LDL. It can be speculated
that both high levels of IDL as well as the prolonged circulation
and exposure of renal and extrarenal tissue to these lipoproteins
could result in atherosclerosis and glomerulosclerosis, which
are often found in a variety of nephrotic renal diseases. Al-
though the delayed catabolism of triglyeride-nch lipoproteins
has been very well-established, much less is known about the
catabolism of cholesterol and cholesterol-rich lipoproteins.
LDL catabolism has been reported to be either normal [34] or
reduced in nephrotic rats [35]. Extrapolating the results to
humans is problematic, since LDL is not the principal choles-
terol-bearing lipoprotein in rats. If we assume that receptor-
mediated clearance of LDL is also delayed in humans, this
could occur as a result of an abnormality in LDL receptor, or a
defective LDL that binds poorly to the receptor [36]. However,
in the present study the LDL of nephrotic patients did not show
different receptor binding, internalization and degradation as
well as intracellular cholesterol esterification and sterol synthe-
sis as compared to LDL from healthy controls. Since LDL of
nephrotic patients was comparable in lipid composition and
apolipoprotein distribution to LDL from healthy controls, al-
tered cellular uptake is not expected. It should be pointed out
that in most other investigations where compositional change of
the LDL particle was found, the LDL density class also
comprised the IDL density range. The present data in GEC are
consistent with maximal receptor-mediated uptake capacities
for normal LDL reported by Gröne and coworkers [14]. In
comparison to fibroblasts, their GEC cell line also exhibited
uptake capacities of 10 to 15%. Furthermore, GEC also showed
high affinities towards /3-VLDL of cholesterol fed rabbits and
chylomicron remnants, isolated from post-heparin plasma [14].
The LDL-receptor has two independent iigands, apoB-l00
and apoE. In general, the presence of apoE increases the
affinity of the lipoprotein to the receptor. In fact, apoB and
apoE containing IDL show increased uptake in lower concen-
trations than only apoB-100 containing LDL. Due to the higher
apoE content of nephrotic IDL this affinity was further en-
hanced in GEC as compared to fibroblasts when exposed to
these lipoproteins. It has been reported that low density lipopro-
tein receptor-related protein (LRP) binds both apoB- and apoE-
containing lipoprotein particles in vitro [37] and that LRP mediates
uptake of apoE-enriched f3-VLDL in fibroblasts. This raises the
speculation about the presence of another receptor in GEC which
may bind preferentially apoE containing lipoproteins.
In summary, nephrotic syndrome resulted in a substantial
elevation of cholesterol-rich apoE containing IDL. Receptor
mediated uptake in GEC of IDL from nephrotic patients was
enhanced, and higher suppression of intracellular sterol synthe-
sis and enhancement of cholesterol ester formation were found.
In contrast, LDL did not exhibit qualitative abnormalities and
showed normal uptake and intracellular cholesterol metabo-
lism. IDL may therefore play the major role in glomerular lipid
accumulation and development of glomerulosclerosis. It might
also be of clinical value to identify those nephrotic patients who
preferentially accumulate IDL.
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